DR. ALEKSANDAR JANKOV, MD

Plain English
This study tested a drug called eribulin in women with breast cancer who did not have complete cancer remission after receiving initial chemotherapy. Among 126 women, those with triple-negative breast cancer had a 2-year disease-free survival (DFS) rate of 56%, while hormone receptor-positive/HER2-negative women had 83%, and HER2-positive women had 73%. These results show that while eribulin was safe and tolerable, it did not significantly improve survival rates compared to chemotherapy alone. Who this helps: This helps patients with breast cancer who have residual disease after initial chemotherapy.

Plain English
This study looked at a 45-year-old man with a type of cancer called follicular large cell lymphoma who was treated with a medication called denileukin diftitox. After the treatment, he developed a severe and life-threatening skin condition known as toxic epidermal necrolysis, where large areas of skin become damaged and blistered. This case is significant because it's the first time this dangerous skin reaction has been reported in connection with this specific drug, highlighting potential risks for patients using it. Who this helps: This information helps doctors by raising awareness of possible severe side effects for patients taking denileukin diftitox.

Plain English
This study investigated how the drug amiodarone and its metabolite desethylamiodarone can harm lung cells by triggering cell death (apoptosis) and cell damage (necrosis). The researchers found that both substances caused significant cell loss in lung cells, with losses reaching up to 80% after 20 hours at certain concentrations. This is important because it highlights potential risks for patients taking amiodarone, especially at doses that are usually considered safe. Who this helps: This benefits patients who use amiodarone for heart conditions, as well as their doctors in monitoring potential lung complications.